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Systems Pharmacology Modeling of Drug-
induced Hyperbilirubinemia: Differentiating
Hepatotoxicity and Inhibition of Enzymes/
Transporters
K Yang1, C Battista1,2, JL Woodhead1, SH Stahl3, JT Mettetal4, PB Watkins2, SQ Siler1 and BA Howell1
Elevations in serum bilirubin during drug treatment may indicate global liver dysfunction and a high risk of liver failure.
However, drugs also can increase serum bilirubin in the absence of hepatic injury by inhibiting specific enzymes/
transporters. We constructed amechanistic model of bilirubin disposition based on known functional polymorphisms in
bilirubin metabolism/transport. Using physiologically based pharmacokinetic (PBPK)model-predicted drug exposure and
enzyme/transporter inhibition constants determined in vitro, our model correctly predicted indinavir-mediated hyperbilirubi-
nemia in humans and rats. Nelfinavir was predicted not to cause hyperbilirubinemia, consistent with clinical observations.
We next examined a new drug candidate that caused both elevations in serum bilirubin and biochemical evidence of liver
injury in rats. Simulations suggest that bilirubin elevation primarily resulted from inhibition of transporters rather than global
liver dysfunction. We conclude thatmechanistic modeling of bilirubin can help elucidate underlyingmechanisms of drug-
induced hyperbilirubinemia, and thereby distinguish benign from clinically important elevations in serum bilirubin.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Severe drug-induced liver injury increases serum bilirubin.
However, drug-induced hyperbilirubinemia can also be induced
by inhibition of enzymes/transporters that mediate bilirubin
disposition.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Can enzyme/transporter-mediated drug-induced hyperbilirubi-
nemia be predicted by mechanistic modeling from in vitro inhibi-
tion data? Can a mechanistic model differentiate bilirubin increases
due to overt liver injury vs. enzyme/transporter inhibition?
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 The mechanistic bilirubin model, combined with PBPK
model-predicted drug exposure and in vitro enzyme/transporter
inhibition constants, correctly predicted indinavir-mediated
unconjugated hyperbilirubinemia and minimal bilirubin
changes by nelfinavir. CKA induced ALT and bilirubin eleva-
tions in rats, and simulations suggest that CKA-mediated biliru-
bin elevation was mostly due to inhibition of bilirubin
transporters, rather than liver injury.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 Mechanistic modeling that represents hepatotoxicity
mechanisms and enzyme-mediated and transporter-mediated
bilirubin disposition can be used to elucidate underlying
mechanisms of drug-induced hyperbilirubinemia and may be
useful in prospective prediction of bilirubin increases by drug
candidates.
Bilirubin, the product of heme breakdown from red blood cells,
is exclusively eliminated by the liver. Thus, circulating bilirubin is
widely used as a diagnostic biomarker for liver function. Large
postmarketing studies of patients with drug-induced liver injury
(DILI) show that 10% of subjects with hyperbilirubinemia or
jaundice die or require a liver transplant.1–3 In the setting of a
clinical trial of a new drug candidate, elevations in serum biliru-
bin may also indicate severe liver injury with global hepatic dys-
function. The 2009 US Food and Drug Administration guidance
on assessing liver safety in clinical trials defines the “Hy’s Law
Case” as a trial subject who experiences a hepatocellular injury
with concomitant elevations in serum alanine aminotransferase
(ALT) >33 the upper limit of normal (ULN) and serum total
bilirubin (TB) elevation >23 ULN when there is no more likely
cause than the study drug. The existence of Hy’s Law Cases in a
clinical trial database is interpreted as indicating that the study
drug is capable of causing liver failure, a conclusion that can lead
to termination of the development program, requirement of
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extended clinical trials to assess risk management strategies, or
restricted indications. Therefore, the observation of hyperbiliru-
binemia during clinical trials or postmarketing can raise concern
about irreversible liver injury with serious regulatory consequences.
However, drug-induced hyperbilirubinemia is not always indic-
ative of hepatotoxicity. Drugs may also increase serum bilirubin
in the absence of hepatic injury by inhibiting enzymes/
transporters that are involved in hepatic elimination of bilirubin.
Serum bilirubin consists of conjugated bilirubin (CB) and uncon-
jugated bilirubin (UB). UB is released to the circulation with red
blood cell degradation and is taken up into hepatocytes by active
transport (organic anion transporting polypeptide (OATP)1B1/
1B3) and passive diffusion.4–6 Once inside the hepatocytes, UB is
metabolized to CB (glucuronide conjugate, primarily) by UDP
glucuronosyltransferase (UGT)1A1.7 Liver-generated CB is
excreted into bile by multidrug resistance-associated protein
(MRP)2, or transported back to sinusoidal blood by the efflux
transporter MRP3, and then taken up again by downstream hepa-
tocytes by OATP1B1/1B3.6,8–10 Patients with inherited disorders
of bilirubin metabolism and/or transport (e.g., Rotor Syndrome
(RS), Gilbert’s Syndrome (GS), Crigler-Najjar Syndrome (CNS),
and Dubin-Johnson Syndrome (DJS)) exhibit elevated serum
bilirubin, suggesting that modulation of any of these enzyme-
mediated and transport-mediated processes by drugs may increase
serum bilirubin (Figure 1).8,11–14 Several studies have reported
that drugs with potent in vitro inhibition for enzyme/transporters
that mediate bilirubin disposition at clinical exposure levels are
associated with hyperbilirubinemia.15–17
Although the inhibitory potential for bilirubin enzyme/
transporters can be assessed using in vitro studies, it remains a
challenge to translate these in vitro data to in vivo and to predict
the net effects of inhibition of multiple steps involved in biliru-
bin disposition. In addition, interpretation is not straightforward
when hyperbilirubinemia is observed with and without concomi-
tant serum ALT elevations in clinical trials. This is because some
drugs without hepatic liabilities can cause high and frequent ele-
vations in serum ALT.1 In such cases, distinguishing hyperbiliru-
binemia that is mediated by liver injury from enzyme/
transporter-mediated interaction is challenging.
Mechanistic modeling could provide a useful tool to investigate
the underlying mechanisms of hyperbilirubinemia and/or predict
this multifactorial event. DILIsym (the product of a public-
private partnership involving scientists from industry, academia,
and the US Food and Drug Administration) is a mechanistic,
multiscale model of DILI that integrates pharmacokinetic and in
vitro toxicity data to predict in vivo hepatotoxicity in humans
and preclinical animals.18 DILIsym can leverage existing preclini-
cal and clinical data to predict the risk of hepatocellular DILI
and prioritize drug candidates, and help optimize dosing para-
digms and monitoring. Construction of SimPops, simulated pop-
ulations that include variability in toxicity mechanisms, enabled
prediction of low-frequency injuries as well as characterization of
patients at DILI risk.19,20 The current SimPops represent healthy
subjects, and patients with diabetes or nonalcoholic fatty liver dis-
ease, but do not yet include ethnic differences or age-related
changes nor represent variability in biomarker-related parameters.
The bilirubin submodel within DILIsym was initially designed to
predict hyperbilirubinemia due to severe liver injury.21 In the cur-
rent study, the bilirubin submodels for human and preclinical
species were updated to represent enzyme/transporter-mediated
bilirubin elimination. Serum bilirubin levels in patients and ani-
mals with impaired function of bilirubin enzyme or transport-
er(s) were used to determine the impact of each pathway on the
changes in serum UB and CB. The impact of three compounds,
indinavir, nelfinavir, and an investigational drug (chemokine
receptor antagonist (CKA), 1-(4-chloro-3-(trifluoromethyl)ben-
zyl)-5-hydroxy-1H-indole-2-carboxylic acid),22 on bilirubin levels
was simulated in humans and rats to validate the current model.
Indinavir and nelfinavir are protease inhibitors used to treat
human immunodeficiency virus. Both drugs are known to inhibit
UGT1A1 and OATP1B1,15 but only indinavir is associated with
hyperbilirubinemia.23,24 Altered serum bilirubin levels by indina-
vir and nelfinavir were simulated with DILIsym by combining in
vitro enzyme/transporter inhibition data with in vivo exposure
predicted by physiologically based pharmacokinetic (PBPK)
modeling. CKA was shown to inhibit multiple hepatic transport-
ers.22 CKA showed minimal to modest ALT increase in humans;
whereas it induced dose-dependent serum ALT increases in rats.
Figure 1 Diagrams of hepatobiliary disposition of bilirubin (a) and the bili-
rubin submodel structure within DILIsym (b). CB, conjugated bilirubin; DJS,
Dubin-Johnson Syndrome; GS, Gilbert’s Syndrome; HC, hepatocytes; MRP,
multidrug resistance-associated protein; OATP, organic anion transporting
polypeptide; RBC, red blood cell; RS, Rotor Syndrome; UB, unconjugated
bilirubin; UGT, UDP glucuronosyltransferase.
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Previous modeling with DILIsym using in vivo exposure and in
vitro mechanistic toxicity data correctly predicted species differ-
ences in hepatotoxicity.25 Interestingly, CKA induced hyperbilir-
ubinemia in all the treated rats, whereas ALT elevations were
observed only in a subset of treated rats, suggesting that factors
other than liver injury might have contributed to the bilirubin
increases. In the present study, CKA-mediated effects on serum
bilirubin were simulated using in vitro bilirubin transporter inhi-
bition data, PBPK-predicted exposure, and previously defined
hepatotoxicity mechanistic parameters in simulated human and
rat populations.
RESULTS
Simulation of bilirubin levels in patients with impaired bilirubin
metabolism and transport
The normal range of serum TB is 0.1–1.2 mg/dL, and about
3.0–4.3% of serum TB exists as CB.14 Respective baseline values
in the current bilirubin model are 0.55 mg/dL and 3.6%. The bil-
irubin model parameters were optimized to clinical bilirubin data
in patients with impaired bilirubin metabolism and transport
(Supplementary Table S2 online). RS is a genetic disorder char-
acterized by near-complete loss of OATP1B1/1B3 expression.8
Patients with RS present with conjugated hyperbilirubinemia,
suggesting that (1) there exist non-OATP-mediated hepatic
uptake pathway(s) for UB, and (2) OATP1B1/1B3 is involved
in blood-hepatocyte shuttling of CB. Therefore, hepatic uptake
of UB was represented by both non-OATP and OATP-mediated
uptake processes, and hepatic uptake of CB was represented as an
OATP1B1/1B3-mediated process. The serum TB and percent
serum CB were 2.28–6.91 mg/dL and 56.1–79%, respectively, in
the simulated patients with RS (with 70–95% impaired function
of OATP1B1/1B3), consistent with clinically observed values of
4.42 6 2.18 mg/dL and 62.9 6 12.1% (Figure 2).8
Patients with GS have 30–50% of normal UGT1A1 func-
tion, whereas CNS is a rare genetic disorder with near-complete
loss of UGT1A1 function. Patients with GS or CNS present
with unconjugated hyperbilirubinemia; serum TB levels in
patients with GS increase to 1.8–4 mg/dL, whereas patients with
CNS manifest increased serum TB up to 6–44 mg/dL.12,14 Simu-
lated patients with GS and patients with CNS had impaired
function of UGT1A1 by 30–60% and 70–90%, respectively.
Simulated serum TB in respective groups were 0.84–5.99 and
8.32–13.03 mg/dL and were mostly composed of UB, consistent
with the clinical data (Figure 2).
Patients with DJS, characterized by conjugated hyperbilirubi-
nemia, have mutations in genes encoding MRP2. Patients with
DJS have decreased MRP2 function and adaptive increases in
MRP3 expression.12 Thus, the simulated patients with DJS had
impaired function of MRP2 by 50–90%, and MRP3 function
increased threefold.26 Patients with DJS manifest with conjugat-
ed hyperbilirubinemia; serum TB often increases up to 2–5 mg/
dL, and, less often, up to 25 mg/dL.27 Simulated serum TB levels
in the patients with DJS were 5.08–13.28 mg/dL, 48–88% of
which is conjugated, consistent with the clinical data (Figure 2).
Overall, simulations reasonably recapitulated conjugated hyper-
bilirubinemia in patients with RS or DJS, and unconjugated
hyperbilirubinemia in patients with GS or CNS.
Simulation of bilirubin levels in rats and mice lacking enzyme
or transporters
The normal range of serum TB and percent serum CB in rats
and mice were highly variable (Supplementary Table S1 online).
Figure 2 Simulated and observed bilirubin levels in patients with inherited disorders of bilirubin metabolism and transport. Top panels represent
observed (closed circles)8,11–14,27 and simulated (open circles) serum total bilirubin (TB) levels. Bottom panels represent observed (closed circles) and
simulated (open circles) percent conjugated bilirubin (CB) in serum compared to serum TB. Multiple simulated individuals for each condition represent
individuals with impaired enzyme/transporter function to a different extent within the ranges. Simulated patients have 70–95% impaired OATP1B1/1B3
function (Rotor Syndrome (RS)), 30–60% impaired UGT1A1 function (Gilbert’s Syndrome (GS)), 70–90% impaired UGT1A1 function (Crigler-Najjar Syn-
drome (CNS)), or 50–90% impaired MRP2 function (Dubin-Johnson Syndrome (DJS)), respectively. Asterisks (*) represent less frequently observed serum
TB ranges in patients with CNS or DJS.
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The baseline values of serum TB and percent serum CB in the
current bilirubin model are 0.55 mg/dL and 3.6%, consistent
with humans. The bilirubin model parameters were optimized to
the bilirubin data in rats and mice lacking specific enzyme and/or
transporter(s) that are involved in bilirubin disposition (Supple-
mentary Table S2 online). Simulations recapitulated conjugated
hyperbilirubinemia in Mrp2-deficient (TR-), Eisai hyperbilirubi-
nemic rat (EHBR), and Mrp2-knockout rats, which have
impaired function of Mrp2 (observed and simulated serum TB:
1.9–4.0 vs. 3.3–6.4 mg/dL), unconjugated hyperbilirubinemia in
Gunn rats with impaired function of Ugt1a1 (observed vs. simu-
lated serum TB: 4.7–8.0 vs. 1.6–4.8 mg/dL), and Ugt1a1
knockout mice (observed vs. simulated serum TB: 7.8 6 1.3 vs.
1.3–3.0 mg/dL; Figure 3).
The mouse bilirubin submodel recapitulated altered serum bili-
rubin levels in mice lacking single or multiple transporters;
knockout of Mrp2 caused a modest increase in serum TB
(observed vs. simulated changes from the baseline: 1.7-fold vs.
3.4-fold, respectively).8 Knockout of Oatp1a/1b significantly
increased serum TB (observed vs. simulated: 8.3-fold vs. 8.5-fold),
which is reversed by additional knockout of Mrp3 (observed vs.
simulated: 3.1-fold vs. 2.6-fold), but potentiated by additional
knockout of Mrp2 (observed vs. simulated: 21.9-fold vs. 12.5-
fold; Figure 4). Due to large variability in the mouse data, fold-
Figure 3 Simulated and observed bilirubin levels in rats lacking Mrp2 or Ugt1a1, and mice lacking Ugt1a1. Closed and open circles represent observed
and simulated serum total bilirubin (TB), respectively. (a) Observed data represent mean serum TB in Mrp2 knockout rats, EHBR rats, and TR- rats (top to
bottom).41,46 Simulated rats have 50–100% impaired Mrp2 function. (b) Observed data represent mean serum TB in Ugt1a1 knockout rats obtained from
multiple studies.39,42,43,47 Simulated rats have 50–100% impaired Ugt1a1 function. (c) Observed data represent mean serum TB in Ugt1a1(-/-) (top) and
Ugt1a1 (1/-) mice (bottom).44 Simulated mice have 50–100% impaired Ugt1a1 function.
Figure 4 Simulated and observed bilirubin levels in mice lacking single or multiple transporters. Observed (closed bars)8 and simulated (open bars)
serum total bilirubin (TB) (a), percent conjugated bilirubin (CB) in serum compared to serum TB (b), and biliary excretion of TB presented as percent of wild-
type animals (c).
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change from the baseline was used for model optimization and
validation to data.
Simulation of indinavir-mediated hyperbilirubinemia
Indinavir is predominantly eliminated by CYP3A4-mediated
metabolism. Nonlinear pharmacokinetic profiles were observed
at therapeutic doses (400–800 mg) due to saturation of hepatic
CYP3A4.28 Incorporation of saturable metabolism reasonably
captured observed nonlinear pharmacokinetics in humans and
rats; peak plasma concentration (Cmax) and area under the curve
(AUC) were within 1.5-fold of those from the mean observed
plasma concentrations in humans and rats (Supplementary Fig-
ure S1 online).
Simulations reasonably predicted increases in serum bilirubin
(mostly UB) in normal patients after administration of indinavir.
After administration of 800 mg indinavir t.i.d. for 1 month, simula-
tions predicted unconjugated hyperbilirubinemia (pretreatment and
post-treatment serum TB: 0.55 and 0.70 mg/dL, respectively), which
is consistent with reported clinical data (pretreatment and post-
treatment serum TB: 0.5 6 0.28 and 0.84 6 0.36 mg/dL, respec-
tively; Figure 5).23 Simulations also predicted that indinavir-induced
hyperbilirubinemia is more pronounced in individuals possessing GS
alleles, consistent with the clinical data; simulated serum TB in
patients with GS administered 800 mg indinavir t.i.d. for 1 month
was 2.346 1.51 mg/dL, whereas the observed value combined from
multiple studies was 2.066 1.79 mg/dL (Figure 5).23,24
After oral administration of four doses of 240 mg/kg indinavir
every 8 h, simulations predicted unconjugated hyperbilirubinemia
(pretreatment and post-treatment serum TB: 0.55 and 0.80 mg/
dL; 1.45-fold increase). Simulated fold-change in serum TB was
consistent with reported preclinical data (pretreatment and post-
treatment serum TB: 0.050 6 0.002 and 0.070 6 0.003 mg/dL,
respectively; 1.4-fold increase).
Simulation of nelfinavir effects on serum bilirubin
Simulated nelfinavir serum profiles reasonably described the
observed data in humans (Supplementary Figure S1 online).
Simulated plasma Cmax and AUC were within 1.4-fold of those
from the mean observed plasma concentrations in humans.29,30
Nelfinavir was shown to inhibit UGT1A1 and OATP1B1 in
in vitro assays, but is not associated with drug-induced hyperbilir-
ubinemia (Table 1). Simulation of clinical dosing of nelfinavir
(1,250 mg b.i.d. for 1 month) did not increase serum TB, consis-
tent with clinical data.
Species differences in chemokine receptor antagonist-
mediated hyperbilirubinemia
In the human SimPops administered single doses of up to
900 mg CKA, serum bilirubin did not exceed the ULN for any
simulated individual, consistent with the clinical data. Converse-
ly, the rat SimPops predicted dose-dependent serum bilirubin ele-
vations at 50–500 mg/kg doses, consistent with preclinical data,
although the magnitude of increase was underestimated
(Figure 6a). In the preclinical studies, the mean fold-increase in
serum TB was 2.1, 3.9, and 5.6 at 50, 200, and 500 mg/kg doses,
respectively. Simulations predicted average serum TB increase of
1.4, 1.7, and 2.1-fold at respective doses (Figure 6a). When the
same dosing protocols were simulated without considering inhibi-
tion of bilirubin transporters, serum TB levels minimally
changed; predicted fold-increase in serum TB was 1.0, 1.1, and
1.2 at respective doses (Figure 6b). On the other hand, simula-
tions with only bilirubin transporter-inhibition constants pre-
dicted 1.4-fold, 1.7-fold, and 1.9-fold increase in serum TB at
Figure 5 Indinavir-mediated hyperbilirubinemia in normal patients and
patients with Gilbert’s syndrome (GS) administered 800 mg indinavir t.i.d.
for 1 month. For the data reported by Rotger et al.,24 boxes represent
25th–75th percentile of the observed data, and whiskers represent the
minimum and maximum observed data; serum total bilirubin (TB) levels in
individuals with heterozygote and homozygote for GS alleles are presented
separately. Zucker et al.23 reported individual TB levels, which are repre-
sented with closed circles; the whisker represents the median value. Sim-
ulated normal individuals have unimpaired UGT1A1 function, whereas
simulated patients with GS have 40–60% impaired UGT1A1 function.
Table 1 Summary of inhibition constants of indinavir, nelfinavir,
and chemokine receptor antagonist for enzymes and transport-
ers involved in bilirubin disposition
Enzyme/transporter Indinavir Nelfinavir CKA
OATP1B1 IC50 (lM) 4.1 6 1.8
a 2 6 0.9a 0.90b
OATP1B3 IC50 (lM) >100
a >100a N/A
UGT1A1 IC50 (lM) 6.86 1.0
c 4.8 6 0.1c N/A
MRP2 IC50 (lM) >100
d >100d 68.56 7.3e
MRP3 IC50 (lM) N/A N/A 11.2
f
CKA, chemokine receptor antagonist, N/A, not available.
aDetermined from HEK cells transfected with OATP1B1 or OATP1B3 using pitavas-
tatin as a probe substrate.15 bThe average of IC50 values from two independent
studies (0.84 and 0.97 lM, respectively), each performed in triplicate. Inhibition of
OATP1B1 activity was determined in a stably transfected HEK293 cell line that
overexpressed the transporter using the probe substrate estradiol 17b-glucuronide
(EG). CKA at varying concentrations was pre-incubated for 15 min at 378C, followed
by a 2-min incubation in presence of CKA and 5 lM EG at 378C. EG was quantified
via liquid chromatography mass spectrometry. cDetermined from the human liver
microsome using b-estradiol as a probe substrate.15 dDetermined using MRP2
PREDIVEZ kit (Solvo) and (5(6)-carboxy-20,70 -dichlorofluorescein (CDF)) as a probe
substrate.15 eData represent geometric mean and SD of four separate test occa-
sions, each performed in duplicate. Effects of CKA on Mrp2 activity were deter-
mined by quantifying inhibition of ATP-dependent uptake (5 min, 378C) of 10 lM
CDF into inverted plasma membrane vesicles prepared from Sf21 insect cells
expressing Mrp2. CDF was quantified via fluorescence.22 fDetermined from one
independent study performed in triplicate. Inhibition of MRP3 activity was deter-
mined from inverted membrane vesicles prepared from HEP293 cells expression
MRP3 using EG as a probe substrate.
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respective doses, indicating that bilirubin transporter inhibition
was the main contributor to the simulated serum TB increase.
DISCUSSION
Drug-induced hyperbilirubinemia may occur because of severe
DILI. The bilirubin submodel within DILIsym, which was ini-
tially designed to predict impaired liver function, reasonably reca-
pitulated hyperbilirubinemia induced by hepatotoxic compounds,
such as troglitazone.20 However, drugs may increase serum biliru-
bin by inhibition of enzymes and/or transporters involved in bili-
rubin disposition in the absence of overt liver injury. In the
current study, the bilirubin submodels for human and preclinical
species were updated to represent enzyme-mediated and
transporter-mediated bilirubin disposition; simulated quantitative
effects of impaired function of enzymes/transporters on serum
bilirubin levels were optimized using in vivo bilirubin data from
humans and animals with impaired bilirubin metabolism and
transport. Next, the impact of multiple enzyme/transporter
inhibitors, indinavir, nelfinavir, and CKA, on serum bilirubin
was simulated by combining PBPK-predicted drug disposition,
the bilirubin model constructed in this study, and inhibition con-
stants for enzyme and/or transporters measured in vitro. CKA
simulations also incorporated known hepatotoxicity mechanisms
to simulate net effects of liver injury and inhibition of bilirubin
disposition. For each compound, simulated bilirubin levels were
compared to in vivo preclinical/clinical bilirubin data to assess
the predictive performance of the current bilirubin model.
Depending on the main bilirubin species in serum, hyperbiliru-
binemia is classified as unconjugated or conjugated hyperbilirubi-
nemia. Two main reasons for unconjugated hyperbilirubinemia
are increased bilirubin production (e.g., hemolytic anemias,
hemolysis) and defective hepatic bilirubin metabolism. The cur-
rent bilirubin submodel reasonably recapitulated unconjugated
hyperbilirubinemia in patients with GS and CNS, Gunn rats,
and Ugt1a1 knockout mice (Figures 2 and 3). Conjugated
hyperbilirubinemia can result from defective hepatobiliary trans-
port of CB, such as cholestatic defects, biliary obstruction, and
genetic disease, including DJS and RS. Patients with RS present
near complete loss of OATP1B1/1B3 function. At first glance, it
seems counterintuitive that impaired function of the uptake
transporter increases serum CB because CB is generated in the
liver and mostly excreted into bile via MRP2. The study by van
de Steeg et al.8 suggested that although most of the CB is eventu-
ally excreted into bile, CB may undergo liver-blood circulation to
transfer CB from upstream hepatocytes to downstream hepato-
cytes. In the recirculation process, MRP3 mediates the efflux of
CB from hepatocytes to sinusoidal blood, and OATP1B1/1B3
mediates reuptake of CB into the downstream hepatocytes. As a
result, inhibition of OATP1B1/1B3 prevents reuptake of CB,
leading to conjugated hyperbilirubinemia. By representing the
cycling of CB between liver and sinusoidal blood, conjugated
hyperbilirubinemia in patients with DJS and RS were reasonably
reproduced with the current bilirubin submodel (Figure 2).
Interestingly, a search for endogenous markers for OATP1B1/
1B3-mediated drug-drug interaction reported that serum UB and
CB are sensitive markers for OAPT1B1/1B3 inhibition by rifam-
pin.31 Altogether, these data support the role of OATP1B1/1B3
in hepatic uptake of both UB and CB.
Indinavir and nelfinavir inhibit UGT1A1 and OATP1B1, but
only indinavir has been associated with hyperbilirubinemia. Sim-
ulations reasonably predicted indinavir-mediated unconjugated
hyperbilirubinemia in normal patients, which was more pro-
nounced in individuals possessing GS alleles, consistent with the
clinical data.23,24 Rotger et al.24 reported a similar extent of
increase in median bilirubin levels between normal subjects and
patients with GS treated with atazanavir or indinavir (0.75 vs.
0.7–1.0 mg/dL), suggesting that higher bilirubin increases in
patients with GS result from additive effects of impaired
UGT1A1 function and indinavir-mediated UGT1A1/
OATP1B1 inhibition. On the other hand, Zucker et al.23
reported greater bilirubin increases in patients with GS compared
with normal subjects after indinavir treatment (1.36 6 1.05 vs.
0.39 6 0.3 mg/dL), suggesting synergistic effects. Simulations
predict slightly greater bilirubin increase in patients with GS
Figure 6 Simulated and observed peak serum total bilirubin (TB) levels in rats administered 50, 200, or 500 mg/kg chemokine receptor antagonist
(CKA). (a) Maximum serum TB fold-change from baseline for increasing doses of CKA. Black dots represent data from preclinical trials and red asterisks
denote simulation results for SimPops (n 5 294) with combined effects of hepatotoxicity and bilirubin transporter inhibition. (b) Maximum serum TB fold-
change from baseline for increasing doses of CKA simulated with combined effects of hepatotoxicity and bilirubin transporter inhibition, hepatotoxicity
only, or bilirubin transporter inhibition only.
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compared with normal subjects (0.21–0.30 vs. 0.14 mg/dL),
which is more consistent with the Rotger et al.24 data. Underly-
ing reasons for the seemingly synergistic increase in patients with
GS reported by Zucker et al.23 still remain to be investigated.
The current model also correctly predicted the minimal impact
of nelfinavir on serum bilirubin. Although the inhibition potency
and systemic exposure were comparable, nelfinavir showed higher
protein binding (fraction unbound in plasma: 0.001 vs. 0.36),
which led to lower unbound concentrations in the liver and sinu-
soidal blood, which mainly contributed to differential effects on
serum bilirubin.15
CKA induced dose-dependent serum ALT and bilirubin eleva-
tions in rats, whereas only modest increases in ALT and no bili-
rubin increases were observed in humans. In vitro assays showed
that CKA inhibited multiple bile acid and bilirubin transporters,
inhibited mitochondrial electron transport chain (ETC) func-
tion, and induced oxidative stress.22,25 Our previous modeling
using DILIsym correctly predicted minimal ALT elevations in
humans up to 900 mg, and dose-dependent, reversible ALT ele-
vations in rats administered single oral doses of 50–500 mg/kg
CKA.25 CKA modeling with its hepatotoxic mechanistic data
combined with bilirubin transporter inhibition correctly pre-
dicted minimal bilirubin increases in humans up to 900 mg, and
dose-dependent bilirubin increases in rats at 50–500 mg/kg,
although fold-changes were underestimated. To determine the
underlying mechanism of bilirubin increase in rats, simulations
were performed either only with hepatotoxic mechanistic inputs
or only with bilirubin transporter inhibition. Simulation results
indicate that, although ALT and bilirubin were concomitantly
increased, bilirubin increases were mostly due to OATP1B1 and
MRP2 inhibition, with minor contributions from liver injury. A
previous study22 showed no histological features indicative of
overt hepatotoxicity in rats administered up to 500 mg/kg CKA,
supporting the conclusion of the current study. Reasonable pre-
diction of serum ALT, a biomarker of liver injury, also validates
the quantitative contribution of liver injury assessed by the cur-
rent model.25
Differences between observed and simulated fold-change bili-
rubin levels in rats administered CKA are likely due to multiple
reasons. The main reason is a lack of metabolite effects in the
simulations. CKA glucuronide was also shown to be a potent
inhibitor of MRP2, but disposition of CKA glucuronide was not
represented in the PBPK framework due to a lack of available
pharmacokinetic data. If the metabolite had been included, it is
very likely that bilirubin levels would have further increased in
the simulations. Another reason could be lack of variability in
parameters surrounding the bilirubin model. As currently mod-
eled, all individuals in the SimPops have the same initial bilirubin
parameter values and variability in bilirubin metabolism and
transport processes were not represented, which leads to minimal
bilirubin variability in the simulation results. By design, SimPops
were constructed to represent variability in a large number of
parameters related to toxicity mechanisms. If parameters related
to biomarkers (e.g., bilirubin disposition) are also varied, it would
require much larger populations (thousands instead of hundreds)
to cover all the parameter spaces, which would significantly
increase computation time.
Not representing metabolite effects and interindividual vari-
ability in bilirubin disposition are limitations of the current
study. Assessment of metabolite effects on hepatotoxicity and
enzyme/transporter function could provide reliable predictions,
but identification and synthesis of stable metabolites are not fea-
sible especially during early stages of drug development. Also,
future efforts will be needed to incorporate variability in baseline
bilirubin levels, variability in multiple bilirubin disposition path-
ways, as well as environmental effects, such as caloric intake,32,33
which may potentially impact serum bilirubin levels. Accurate
prediction of the drug concentration in the liver is important in
predicting inhibition of hepatic enzyme/transporters, but clinical
measurement of liver concentration is challenging and there
exists uncertainty in PBPK-predicted liver concentrations of the
hepatic uptake transporter substrates based on the plasma pro-
file.34 In the current study, nelfinavir liver concentrations were
predicted using a PBPK model trained to the plasma concentra-
tions, which is another limitation. To explore the potential
impact of the uncertainly in liver concentration, simulations were
performed with up to 10-fold increases in nelfinavir liver concen-
trations. Nelfinavir still did not induce hyperbilirubinemia, sup-
porting our overall conclusion.
Drugs may induce hyperbilirubinemia due to liver injury, inhi-
bition of bilirubin enzymes and transporters, or a combination of
both. Observations of drug-induced hyperbilirubinemia in clini-
cal trials often require thorough assessments of hepatotoxic
potential and investigation of underlying mechanisms. This
would involve measurement of in vivo liver safety biomarkers and
mechanistic in vitro studies. Given the complexity of underlying
mechanisms and multifactorial nature of drug-induced hyperbilir-
ubinemia, interpretation and translation of various data is not
always straightforward. In the current study, a quantitative sys-
tems pharmacology model that incorporates drug disposition, the
hepatocyte life cycle, multiple hepatotoxic mechanisms, and
mechanistic biomarker models was used to assess underlying
mechanisms of drug-induced hyperbilirubinemia. Differential
effects of indinavir and nelfinavir on serum bilirubin were
correctly predicted, and species differences in CKA-mediated
hyperbilirubinemia were reasonably reproduced. Simulations also
suggested that bilirubin increases in rats administered CKA were
mainly due to bilirubin transporter inhibition with some contri-
bution of liver injury, demonstrating that the current approach
may be useful in predicting potential hyperbilirubinemia
and assess underlying mechanisms for observed bilirubin increase
in vivo.
METHODS
DILIsym bilirubin submodel update
Representation of bilirubin disposition in DILIsym prior to version 5A
was published elsewhere and also described in the Supplementary Meth-
ods online.21 In the current study, the bilirubin submodel was updated
explicitly to represent the enzyme-mediated and transporter-mediated
hepatobiliary disposition of bilirubin. In the bilirubin submodel, both
serum and liver bilirubin pools consist of UB and CB. OATP1B1/1B3
facilitates hepatic uptake of UB and CB.4–6 UB can also enter the liver
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by passive diffusion.35,36 Conversion of UB to CB in the liver is mediat-
ed by UGT1A1.7 CB is excreted into bile via MRP2 or transported to
sinusoidal blood by MRP3.9 Each of the enzyme-mediated or
transporter-mediated processes can be competitively inhibited by drugs
or metabolites. Inhibition of OATP1B1/1B3 is dependent on the
unbound drug concentration in hepatic inlet, which is the weighted
average (by blood flow rate) of the portal vein concentration and the
hepatic artery concentrations. Inhibition of UGT1A1, MRP2, and
MRP3 is dependent on the unbound drug concentration in the liver.
Renal excretion and intestinal secretion pathways are added as compen-
satory excretion pathways for CB and UB, respectively, under
hyperbilirubinemia.37–40
The human bilirubin submodel was calibrated using bilirubin levels in
humans with inherited disorders of bilirubin metabolism (i.e., GS and
CNS) and transport (RS and DJS).8,11–14,27 Bilirubin submodels for the
rat, mouse, and dog were calibrated using bilirubin levels in preclinical
species lacking specific enzymes or transporters (i.e., TR-, EHBR, Mrp2-
knockout, and Gunn rats; mice lacking Mrp2, Mrp3, Oatp, or Ugt1a1;
and dogs with biliary obstruction).8,39,41–47 Affinities of UB and CB for
enzymes and transporters were obtained from literature or optimized, if
unavailable.4,5,9,48 Parameters in the bilirubin submodel, obtained
from the literature or estimated using serum bilirubin levels, are listed in
Supplementary Table S2 online. Detailed methods for bilirubin submo-
del construction can be found in the Supplementary Method online.
Development of physiologically based pharmacokinetic
models
PBPK models were developed in DILIsym to describe the disposition of
indinavir, nelfinavir, and CKA in humans and rats. Briefly, the PBPK
model consisted of a central compartment representing the blood, three
liver compartments representing three zones of the liver, and extrahepat-
ic tissues (i.e., muscle, gut, and other tissues). Blood and tissue compart-
ments were linked by blood flow. Tissue distribution of indinavir,
nelfinavir, and CKA was represented with tissue partition coefficients;
hepatic distribution of nelfinavir was transporter-mediated. Indinavir
and nelfinavir are mainly eliminated by hepatic metabolism, which is
represented by Michaelis-Menten kinetics. Metabolite disposition was
not tracked because metabolite effects on bilirubin disposition remain
unknown. Thus, it was assumed that only the parent modulated biliru-
bin disposition. Drug-specific parameters, obtained from the literature or
estimated using available plasma and/or liver PK profiles of indinavir
and nelfinavir, are listed in Supplementary Table S3 online. PBPK
parameters for CKA were previously reported.25 Physiological parame-
ters for tissue volumes and blood flows in the PBPK submodel of DILI-
sym were published elsewhere.49
Simulation of drug-induced hyperbilirubinemia
Indinavir-mediated hyperbilirubinemia was simulated in the baseline
human and the baseline rat using PBPK model-predicted exposure and
in vitro inhibition constants for UGT1A1, OATP1B1, and MRP2
(Table 1). In human simulations, the baseline human and a simulated
patient with GS, which possess decreased UTG1A1 function by 40–
60%, were orally administered 800 mg indinavir three times per day for
1 month. In rat simulations, the baseline rat was administered a total of
four oral doses of 240 mg/kg indinavir every 8 h. Nelfinavir-mediated
hyperbilirubinemia was simulated in the baseline human administered
1,250 mg nelfinavir b.i.d. for 1 month using PBPK model-predicted
exposure and in vitro inhibition constants for UGT1A1, OATP1B1,
and MRP2 (Table 1). CKA-mediated hyperbilirubinemia was simulated
in the human (600 and 900 mg single oral dose) and rat (50, 200, and
500 mg/kg single oral dose) SimPops using PBPK model-predicted expo-
sure, in vitro inhibition constants for OATP1B1 and MRP2 (Table 1),
and previously determined in vitro mechanistic toxicity data.25
Additional Supporting Information may be found in the online version of
this article.
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